a rapid-acting and more abusable opioid, there is a risk that in the future a technique could be discovered to convert NKTR-192 into a rapid-acting and more abusable opioid which would significantly diminish the value of this drug candidate; (iv) the FDA and other regulatory agencies could impose significant risk mitigation requirements that hamper market acceptance of NKTR-192, even if approved